Chimeric Antigen Receptor T‐Cell Therapy: More Than an Anti‐Cancer Drug
ABSTRACT Initially, chimeric antigen receptor (CAR) T‐cell therapy was developed to eliminate malignant B cells in haematological B‐cell malignancies by targeting CD19 and B‐cell maturation antigen. This approach achieved notable success, resulting in (malignant) B‐cell depletion and inducing clinical remission in cancer patients.
Hannah C. M. Schenk +8 more
wiley +1 more source
Background Severe osteonecrosis of the femoral head (ONFH) secondary to corticosteroid therapy in symptomatic, hematological young patients currently has no therapeutic alternative, and early total hip replacement (THR) is a high‐risk intervention in those patients.
Enrique Gómez-Barrena +12 more
wiley +1 more source
Tissue-Resident Myeloid and Histiocytic Cells in Health and Disease: Novel Emerging Concepts. [PDF]
Valent P +27 more
europepmc +1 more source
Targeting the Spleen as an Alternative Site for Hematopoiesis [PDF]
Lim, Hong +3 more
core +1 more source
FACS-Based Assessment of Human Hematopoietic Stem and Progenitor Cells. [PDF]
Schmachtel T, Bonig H, Rieger MA.
europepmc +1 more source
Unveiling the phenotypic impact of cryopreservation on adipose derived stem cells: A systematic review. [PDF]
Farhana S +4 more
europepmc +1 more source
Establishing disease-specific thresholds for automated hematopoietic progenitor cell counting in hematological malignancies. [PDF]
Taka O, Thedsawad A, Owattanapanich W.
europepmc +1 more source
Real-time immunophenotypic shifts in pediatric B lymphoblastic leukemia providing implications for minimal residual disease detection. [PDF]
Javed O +7 more
europepmc +1 more source
The Flow Cytometric Evaluation of B- and T-Lymphoblastic Leukemia/Lymphoma. [PDF]
Dorfman DM.
europepmc +1 more source

